Related references
Note: Only part of the references are listed.Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
Alice Bernard-Tessier et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Adrenocortical carcinoma: current treatment options
Giuseppina De Filpo et al.
CURRENT OPINION IN ONCOLOGY (2021)
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Harold J. Burstein
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
Riikka Oksala et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Prostate Cancer, Version 2.2019
James L. Mohler et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling
Jan M. Moll et al.
PROSTATE (2019)
Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research
Liyu Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: A comprehensive review
Lina Schiffer et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2019)
Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies
Maria Fleseriu et al.
PITUITARY (2016)
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Anitha B. Alex et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Human Steroid Biosynthesis for the Oncologist
Mary Louise Auchus et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2016)
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous et al.
GENOME BIOLOGY (2016)
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
Fred Saad et al.
LANCET ONCOLOGY (2015)
Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors
Eddy J. Chen et al.
CLINICAL CANCER RESEARCH (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors
Stephen W. Rafferty et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development
K. L. R. Brouwer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
Nicholas Mitsiades et al.
CANCER RESEARCH (2012)
Human adrenocortical carcinoma cell lines
Tao Wang et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
Joanne Bowes et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
Changmeng Cai et al.
CANCER RESEARCH (2011)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Mutation of mouse Cyp11a1 promoter caused tissue-specific reduction of gene expression and blunted stress response without affecting reproduction
Meng-Chun Shih et al.
MOLECULAR ENDOCRINOLOGY (2008)
P-glycoprotein and breast cancer resistance protein: Two dominant transporters working together in limiting the brain penetration of topotecan
Nienke A. de Vries et al.
CLINICAL CANCER RESEARCH (2007)
Androgen receptor amplification is associated with increased cell proliferation in prostate cancer
Kyllikki Haapala et al.
HUMAN PATHOLOGY (2007)
Multiple signaling pathways regulating steroidogenesis and steroidogenic acute regulatory protein expression: More complicated than we thought
DM Stocco et al.
MOLECULAR ENDOCRINOLOGY (2005)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin
A Slominski et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2004)
The influence of the amino acid substitution 198K on the catalytic activity of baboon cytochrome P450 side-chain cleavage (CYP11A1)
KH Storbeck et al.
ENDOCRINE RESEARCH (2004)
The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective
TD Bjornsson et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1
MC Hu et al.
MOLECULAR ENDOCRINOLOGY (2002)
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer
K Steketee et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
XY Zhao et al.
NATURE MEDICINE (2000)
Share Paper
